Kuntai Capsule plus Hormone Therapy vs. Hormone Therapy Alone in Patients with Premature Ovarian Failure: A Systematic Review and Meta-Analysis
Joint Authors
Liu, Weiping
Nguyen, Truong-Nam
Tran Thi, Thu-Van
Zhou, Shaohu
Source
Evidence-Based Complementary and Alternative Medicine
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-06-26
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
The aim of this study was to evaluate the efficacy and safety of Kuntai capsules (KTC) plus hormone therapy (HT) compared to HT alone for the treatment of premature ovarian failure (POF).
Databases including PubMed, MEDLINE, Web of Science, China National Knowledge Infrastructure (CNKI), the Chinese BioMedical database (CBM), and the Wanfang database were searched up to October 2018 for randomized controlled trials (RCTs).
After screening the studies, extracting the data, and assessing the study quality, Cochrane RevMan 5.3 software was used to conduct a meta-analysis.
Twelve RCTs involving 1178 patients were included.
Regarding the therapeutic effects, total effective treatment rate was higher for the KTC+HT groups compared to the HT-only groups.
Furthermore, compared with HT, KTC+HR effectively altered endocrine indexes involving serum levels of luteinizing hormone (weighted mean difference [WMD]=-3.47, 95% CI [5.68, -1.26], P=0.002]), follicle-stimulating hormone [WMD=-8.15, 95% CI [-10.44, -5.86], P<0.00001], estrogen [WMD=17.21, 95% CI [10.16, 24.26], P<0.00001], and anti-Müllerian hormone [WMD=1.07, 95% CI [0.78, 1.36], P<0.00001]; blood lipid indexes involving serum levels of triglyceride (WMD=-0.55, 95% CI [-0.76, -0.43], P<0.00001), total cholesterol (WMD=-0.63, 95% CI [-0.74, -0.52], P<0.00001), and low-density lipoprotein cholesterol (WMD=-0.62, 95% CI [-0.75, -0.49], P<0.00001); and B-ultrasound results involving ovarian resistance index (WMD=-0.20, 95% CI [-0.35, -0.04], P=0.01), perfusion index (WMD=-0.41, 95% CI [-0.57, -0.24], P<0.00001), peak systolic velocity (WMD=2.43, 95% CI [1.52, 3.34], P<0.00001), antral follicle count (WMD=1.20, 95% CI [0.41, 2.00], P=0.003), and mean ovarian diameter in the plane containing the longest axis of the ovary (WMD=4.34, 95% CI [2.94, 5.74], P<0.00001).
There were no serious adverse events in either group.
There is evidence that KTC+HT is more effective and safer than HT alone for treating POF.
However, the trials had low methodological quality and small samples, so further standardized research is required.
American Psychological Association (APA)
Liu, Weiping& Nguyen, Truong-Nam& Tran Thi, Thu-Van& Zhou, Shaohu. 2019. Kuntai Capsule plus Hormone Therapy vs. Hormone Therapy Alone in Patients with Premature Ovarian Failure: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine،Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1148815
Modern Language Association (MLA)
Liu, Weiping…[et al.]. Kuntai Capsule plus Hormone Therapy vs. Hormone Therapy Alone in Patients with Premature Ovarian Failure: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine No. 2019 (2019), pp.1-9.
https://search.emarefa.net/detail/BIM-1148815
American Medical Association (AMA)
Liu, Weiping& Nguyen, Truong-Nam& Tran Thi, Thu-Van& Zhou, Shaohu. Kuntai Capsule plus Hormone Therapy vs. Hormone Therapy Alone in Patients with Premature Ovarian Failure: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine. 2019. Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1148815
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1148815